ライフサイエンスコーパス: pharmacogenetics

1 with, previous findings in antihypertensive pharmacogenetics.

2 We provide a current review of opiate pharmacogenetics.

3 hism is one of the most 'mature' examples in pharmacogenetics.

4 This field is referred to as pharmacogenetics.

5 ed, another factor that could influence SULT pharmacogenetics.

6 asic research and in clinical application of pharmacogenetics.

7 g example of the potential clinical value of pharmacogenetics.

8 ional mechanisms not previously described in pharmacogenetics.

9 tility for linkage-disequilibrium mapping in pharmacogenetics.

10 s, developmental regulation, toxicology, and pharmacogenetics.

11 , illustrates the promise and limitations of pharmacogenetics.

12 d theories of biogenic amine dysfunction and pharmacogenetics.

13 could link to normal reversal learning using pharmacogenetics.

14 onse, which has been increasingly studied in pharmacogenetics.

15 foods remain to be evaluated in light of CYP pharmacogenetics.

16 h particular design features of relevance in pharmacogenetics.

17 tcomes, which are of particular relevance in pharmacogenetics.

18 mechanism of action will lead to advances in pharmacogenetics.

19 l implementation of clopidogrel and warfarin pharmacogenetics.

20 edicine, and future clinical implications of pharmacogenetics.

21 obehavioral mechanisms of naltrexone and its pharmacogenetics.

22 (4) genetics/gene-environment interactions, pharmacogenetics; (5) intervention/prevention/therapeuti

23 The marked racial differences in relevant pharmacogenetics, a potential explanation for differing

24 important implications in the application of pharmacogenetics across a range of common diseases, incl

25 Pharmacogenetics aims to identify individuals predispose

26 Pharmacogenetics analysis showed single nucleotide polym

27 Pharmacogenetics analysis showed that exm-rs1321744 achi

28 or candidate gene association studies, 5 for pharmacogenetics and 21 for biochemical studies.

29 ncluding histocompatibility, immunogenetics, pharmacogenetics and anthropology studies, among many ot

30 Large-scale pharmacogenetics and complex disease association studies

31 driven by genetic variation is a key aim of pharmacogenetics and could influence precision medicine

32 describe recent advances in antihypertensive pharmacogenetics and discuss challenges related to trans

33 Future drug development should include pharmacogenetics and focus on drugs for specific aspects

34 use of SNPs in such diverse applications as pharmacogenetics and genome-wide association studies for

35 tential roles of antiretrovirals, isoniazid, pharmacogenetics and other factors.

36 This review will focus on pharmacogenetics and pharmacogenomics and their role in

37 It is clear that progress in the field of pharmacogenetics and pharmacogenomics will help further

38 f AA in patients treated with TNF inhibitors.Pharmacogenetics and the inherent physiologic levels of

39 prescribing or showed no difference between pharmacogenetics and treatment as usual for clinical and

40 First, using pharmacogenetics and two-photon calcium imaging, we vali

41 ating that each group has different warfarin pharmacogenetics and would benefit from genotype-based d

42 Pharmacogenetics and, more recently, pharmacogenomics ha

43 ocompatibility, immunology, epidemiology and pharmacogenetics) and population genetics.

44 clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient repres

45 n microscopy, morphological reconstructions, pharmacogenetics, and diffusible dye, calcium, and gluta

46 ion--including gene-environment interaction, pharmacogenetics, and genetic counseling--are also discu

47 We discuss metformin, OCT1, pharmacogenetics, and how the integrative genomics revol

48 road implications for personalized medicine, pharmacogenetics, and the meaning of race.

49 ate with advances in genetics, genomics, and pharmacogenetics; and how they can apply this knowledge

50 A pharmacogenetics approach demonstrates that both glutama

51 This study's pharmacogenetics approach strongly implicates the role o

52 erapy response, current candidate gene-based pharmacogenetics approaches require a priori knowledge a

53 REVIEW: The fields of clinical genetics and pharmacogenetics are rapidly expanding.

54 results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of

55 Pharmacogenetics-based dosing regimens is the most power

56 me disease entities, and more will follow as pharmacogenetics becomes increasingly accepted as an imp

57 metabolism, toxicology, medicinal chemistry, pharmacogenetics, biological engineering, and bioremedia

58 Pharmacogenetics can improve medication-related outcomes

59 y provides the first demonstration that host pharmacogenetics can influence therapeutic response in C

60 nes from participants of the Cholesterol and Pharmacogenetics (CAP) simvastatin clinical trial, we fo

61 ved from participants in the Cholesterol and Pharmacogenetics (CAP) study who were treated with simva

62 This novel finding in N-acetylation pharmacogenetics clearly demonstrates a direct link betw

63 Coriell populations and a large ontology of pharmacogenetics concepts.

64 arin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the Univers

65 ntries as part of the International Warfarin Pharmacogenetics Consortium effort.

66 he recently published International Warfarin Pharmacogenetics Consortium pharmacogenetic-based warfar

67 Rapid advances in pharmacogenetics, continuous decrease in genotyping cost

68 parameters, drug interaction parameters, and pharmacogenetics data have been unevenly collected in di

69 g these barriers to routine incorporation of pharmacogenetics data into clinical care.

70 benefits of evolving the schema for storing pharmacogenetics data: ontologies perform well in early

71 ief review, we trace the historical roots of pharmacogenetics, discuss its rapidly evolving processes

72 The current enthusiasm for pharmacogenetics draws much of its inspiration from the

73 in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial

74 For example, emerging research in pharmacogenetics explores how genetic variation in drug-

75 Pharmacogenetics explores the genetic underpinnings of v

76 ch for PD and highlight the applicability of pharmacogenetics for enhancing cellular signaling in rep

77 Leveraging pharmacogenetics for precision medicine and exploring VM

78 ns, but also for routine DNA diagnostics and pharmacogenetics for templates with different annealing

79 hould focus on reasons-perhaps compliance or pharmacogenetics-for those differences.

80 al clinical importance of the translation of pharmacogenetics from bench to bedside, the potential fo

81 Pharmacogenetics genetically re-engineers neurons to pro

82 n a few small studies relating to the use of pharmacogenetics-guided dosing in the initiation of warf

83 current evidence base is either in favor of pharmacogenetics-guided prescribing or showed no differe

84 RECENT FINDINGS: Evidence now suggests that pharmacogenetics has a role in the effects of analgesic,

85 Recent research in antihypertensive pharmacogenetics has added to the existing evidence base

86 The importance of host pharmacogenetics has also been recognised.

87 Pharmacogenetics has been most commonly used in studies

88 Pharmacogenetics has been promoted as potentially provid

89 also summarize recent studies in which TPMT pharmacogenetics has enhanced our understanding of molec

90 Since its first description, the field of pharmacogenetics has expanded to study a broad range of

91 Pharmacogenetics has led to the identification of severa

92 oncology, systematic application of efficacy pharmacogenetics has not been integrated into drug disco

93 Pharmacogenetics has offered compelling evidence toward

94 Pharmacogenetics has the potential to complement therape

95 Over the past half century, pharmacogenetics has--like all of medical genetics--evol

96 The third area, pharmacogenetics, has utility for some therapies today.

97 ic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood

98 TPMT pharmacogenetics highlights the potential clinical impor

99 Pharmacogenetics holds great promise for the optimizatio

100 integration of research on neuroimaging and pharmacogenetics holds promise for improving treatment f

101 techniques, such as excitability studies and pharmacogenetics, holds promise in elucidating the under

102 Pharmacogenetics identifies the likelihood of adverse ev

103 Recently, the Clinical Pharmacogenetics Implementation Consortium (CPIC) have r

104 The Clinical Pharmacogenetics Implementation Consortium (CPIC) is ded

105 vel A evidence as determined by the Clinical Pharmacogenetics Implementation Consortium (CPIC).

106 cogenomics Research Network and the Clinical Pharmacogenetics Implementation Consortium are partnersh

107 portantly, for gene-drug pairs with Clinical Pharmacogenetics Implementation Consortium Guidelines, w

108 study enhances understanding of dolutegravir pharmacogenetics in Africa.

109 cal trials, and ongoing efforts to implement pharmacogenetics in clinical practice.

110 define the role of clopidogrel and warfarin pharmacogenetics in clinical practice.

111 Using optogenetics and pharmacogenetics in combination with in vivo and in vitr

112 gms, and look towards future applications of pharmacogenetics in enhancing the efficiency of the drug

113 y, the potential implications of transporter pharmacogenetics in influencing drug bioavailability are

114 ew Orleans in October 2012, Optogenetics and Pharmacogenetics in Neuronal Function and Dysfunction, b

115 carried out to characterize the role of UGT pharmacogenetics in several types of cancer, and these e

116 hese studies highlight the potential role of pharmacogenetics in the design of a therapeutic plan whi

117 drug pharmacokinetics, pharmacodynamics, and pharmacogenetics in view of the absence of easily measur

118 Pharmacogenetics in warfarin clinical trials have failed

119 ement strategies based on modifier genes, to pharmacogenetics, in which individual genetic informatio

120 In this article, we provide an overview of pharmacogenetics, including pharmacokinetics (PK), pharm

121 tandardized dose escalation, and to evaluate pharmacogenetics influences on PK and PD parameters.

122 The pharmacogenetics-informed approach did not manifest a de

123 These findings indicate that pharmacogenetics-informed dosing of TCAs can be safely a

124 Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT) with antidepre

125 Antiretroviral regimen and pharmacogenetics interactions with study arm were evalua

126 Incorporating pharmacogenetics into clinical practice promises to impr

127 esearch paradigms may be needed to translate pharmacogenetics into clinical tools.

128 antras of scientists working in the field of pharmacogenetics is 'the right dose for the right patien

129 ization of chemotherapy through the study of pharmacogenetics is becoming an ever attainable reality.

130 A synthesis of opto- and pharmacogenetics is beginning to reveal how various inte

131 Pharmacogenetics is being used to develop personalized t

132 Pharmacogenetics is one example of how gene-environment

133 Pharmacogenetics is the study of the role of inheritance

134 Pharmacogenetics is the variability of drug response due

135 The Pharmacogenetics Knowledge Base contains genomic, phenot

136 cially for tricyclic antidepressants (TCAs), pharmacogenetics may be of interest because therapeutic

137 hesia and analgesia generated some hope that pharmacogenetics may guide anesthesiologists to provide

138 Pharmacogenetics may help physicians deliver individuali

139 variants for monitoring treatment response (pharmacogenetics) may usher in a new era of personalized

140 Ultimately, pharmacogenetics might provide a means to individualize

141 beginning to make inroads in gastric cancer pharmacogenetics, mostly through small, pilot retrospect

142 II- study (n = 745, age: 8-21, USA) and the Pharmacogenetics of adrenal suppression cohort (n = 391,

143 atric Asthma Gene Environment Study, and the Pharmacogenetics of Adrenal Suppression with Inhaled Ste

144 While recent advances in pharmacogenetics of adverse drug reactions show promise,

145 Although preliminary work on the pharmacogenetics of alcoholism and its treatment has bee

146 Research into the genetics and pharmacogenetics of asthma and into the societal factors

147 tcomes pediatric participants (n = 100), and Pharmacogenetics of Asthma Medication in Children: Medic

148 med a meta-analysis of three cohort studies: Pharmacogenetics of Asthma Medication in Children: Medic

149 As a first step toward studying the pharmacogenetics of cancer chemotherapy, 51 candidate ge

150 rther research into genetic risk factors and pharmacogenetics of cardiovascular disease associated wi

151 namics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irri

152 In conclusion, pharmacogenetics of CFH Y402H polymorphism may play a ro

153 rge transfusion requirements and the complex pharmacogenetics of clopidogrel may have played a role.

154 will discuss the most recent developments in pharmacogenetics of commonly used perioperative medicati

155 We characterized the pharmacogenetics of dolutegravir exposure after ART init

156 Pharmacogenetics of drug-metabolizing systems continues

157 stigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected

158 eliminary results of this pilot study on the pharmacogenetics of FcgammaR and biological therapy in p

159 We set out to study the pharmacogenetics of human arsenic methyltransferase (AS3

160 We summarize recent progress in the pharmacogenetics of IBD with respect to partitioning pat

161 xicity on study arm, antiretroviral regimen, pharmacogenetics of isoniazid and efavirenz metabolism (

162 The pharmacogenetics of methotrexate (MTX) was investigated

163 sting roles in chemotherapy disposition, the pharmacogenetics of OATPs in cancer therapy, and OATP ov

164 2020, from 45 outpatient MAT clinics in the Pharmacogenetics of Opioid Substitution Treatment Respon

165 Initial research into the pharmacogenetics of psychotropic drug response suggests

166 dependence; however, less is known about the pharmacogenetics of smoking cessation.

167 They also inform the pharmacogenetics of statin treatment by demonstrating th

168 ies to characterize the pharmacodynamics and pharmacogenetics of TAS-103 are warranted.

169 We utilized 2 cohorts to study pharmacogenetics of weight gain following switch from ef

170 We utilized two cohorts to study pharmacogenetics of weight gain following switch from ef

171 ype 3 receptor antagonists and the impact of pharmacogenetics on postoperative nausea and vomiting.

172 We review the impact of pharmacogenetics on therapy in diseases of the colon usi

173 to describe what has heretofore been called pharmacogenetics or chemicogenetics.

174 ic ligand--GPCR pairs (aka DREADDs, RASSLS, 'pharmacogenetics') permits the study of pharmacology usi

175 Pharmacogenetics (PG) could improve dosing efficiency an

176 cant strides have been made in understanding pharmacogenetics (PGx) and gene-drug interactions, there

177 treatment interaction effect for SNP-sets in Pharmacogenetics (PGx) assessments embedded within rando

178 power for whole exome or genome analysis in Pharmacogenetics (PGx) studies with small sample sizes.

179 l implementation of clopidogrel and warfarin pharmacogenetics possible.

180 increasingly apply genomic data analysis to pharmacogenetics, preventive medicine, and patient-targe

181 Pharmacogenetics primarily uses genetic variation to ide

182 As part of a pharmacogenetics project, we screened exons and flanking

183 lines that support the use of cardiovascular pharmacogenetics, provide examples of clinical implement

184 ion has also increased to include aspects of pharmacogenetics relating to pharmacokinetics and pharma

185 nd effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessati

186 t information, are tailored for leading-edge pharmacogenetics research.

187 We collected genetic data from two pharmacogenetics resequencing studies, and formulated qu

188 such unpredictability, defining the field of pharmacogenetics (see Glossary).

189 ARV regimen and pharmacogenetics should also be considered in making dec

190 In the realm of cardiovascular pharmacogenetics, significant advances have identified m

191 5 genes play an especially important role in pharmacogenetics, since they metabolize >50% of the drug

192 MT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to cl

193 Pharmacogenetics studies are the platform for discoverin

194 Genetic sequence data for pharmacogenetics studies can be complex, and the best in

195 Several pharmacogenetics studies have identified an association

196 rom non-responders via genetic predictors in pharmacogenetics studies have not met their anticipated

197 these findings demonstrate the importance of pharmacogenetics studies in veterinary species and sugge

198 mine treatment in a prospective double-blind pharmacogenetics study in first-generation Mexican Ameri

199 ed by Genetic Haplotype Markers) study was a pharmacogenetics study of statin efficacy and safety.

200 This is the largest and most comprehensive pharmacogenetics study to date examining clinical respon

201 nce effects of sex in the Cardiovascular and Pharmacogenetics study.

202 t are particularly important in the field of pharmacogenetics, such as the drug regimen of interest a

203 Pharmacogenetics testing in patients may help differenti

204 Pharmacogenetics, though presently confined to the asses

205 -elevated Sst+ interneuron activity, we used pharmacogenetics to activate or inhibit hippocampal Sst+

206 For pharmacogenetics to deliver on its potential, this compl

207 search into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese pa

208 typic screen can be coupled with current DNA pharmacogenetics to identify the ideal therapeutic agent

209 extension of previous studies of naltrexone pharmacogenetics to individuals of Asian descent, an eth

210 There are continued efforts with pharmacogenetics to predict response and side-effect ris

211 ngs, two-photon microscopy, optogenetics and pharmacogenetics to show how repeated cocaine exposure a

212 Using transgenic mice, optogenetics, and pharmacogenetics, we studied the role of astrocytes on t

213 zapine discontinuation and deaths, and their pharmacogenetics were studied.

214 gly popular, predominantly in the context of pharmacogenetics, where the survival endpoint could be d

215 Pharmacogenetics will complement but not replace traditi

216 Ultimately, pharmacogenetics will give providers the options for imp

217 Future utility for pharmacogenetics will wax or wane depending on the natur

218 Optogenetics with microbial opsin genes, and pharmacogenetics with designer receptors, represent pote

219 y recommended in the guidelines of the Dutch Pharmacogenetics Working Group (ie, the index drug) as p

220 interaction test result for which the Dutch Pharmacogenetics Working Group [DPWG] recommended a chan

221 ived drug or dose adjustments based on Dutch Pharmacogenetics Working Group recommendations.